Food, I am all in as you are, but not concerned about Stoll's vacation. In fact that his vacation schedule was released, was a way of saying the RD-1 crf's remain in process in Germany (perhaps effected by someone else's vacation schedule).
The complexity of data previously acknowledged by Stoll, implies continued analysis. BP is not looking for a yes/no as we are. We are breaking new ground and the study interpretaion will face intense scrutiny by multiple scientific groups. POC is just the beginning. The protocol will also need to be refined for RD reversal/analgesia preservation with iv therapy. I suspect we are still on a fast tract for an academic center in Germany in August.
Stoll and Neuro have previously commented on the recognized expertise in the RD1 study group. Davey just posted:
>>I'm told that the academic group performing the RD-1 study has substantially more experience in RD than the CRO who ran the RD-2 study. In fact, one of the key opinion leaders in the field of RD was involved in the RD-1<<.
I suspect there is more human clinical RD expertise in the RD1 group than with COR + U of Alberta. Pillow talk will not get you far with BP.
News 
Market Data 
Discover 
AI
